Do you have a digital solution to a local healthcare access challenge? You can make a difference!
The Sandoz HACk is a global competition that invites inspirational ideas that use digital technology with the potential to complement – or even disrupt -- established approaches to healthcare access.
Universal access to healthcare remains the single largest unmet medical need. Two billion people don’t have access to the medicines they need. Four hundred million lack access to essential health services.
Simply tell us how digital technology can improve access to medicines in your community. Your idea, no matter how small, can make a big difference, and if selected, we will help you make that happen!
With a focus on innovation through digital technology, our ambition at Sandoz is to create a passionate, ever-active community of entrepreneurially minded individuals committed to improving healthcare access.
What is in it for you?
Sandoz will work with shortlisted entrants to incubate and enhance their ideas, in order to arrive at practical, scalable solutions that help improve people’s lives in communities around the world. Those with the best ideas will travel to South by SouthWest (SXSW; Austin, Texas), in March 2019, to participate in a four-day Accelerator event, to evolve their ideas into an actionable business plan. The winner will receive seed funding and support from Sandoz to help bring their idea to life.
At least 400 million people worldwide cannot access essential health services and more than 2 billion cannot afford to buy the medicines they need.
At Sandoz, we discover new ways to improve and extend people’s lives. We pioneer novel approaches to help people around the world access high-quality medicine. To achieve this, we pursue an integrated access strategy that focuses our work on improving access to medicines, access to medical information and access to medical capacity building, which includes efforts to provide and support appropriate training for healthcare professionals. In 2015, our products reached an estimated 520 million patients and our aspiration is to reach 1 billion people
In addition to the global #1 ranking in biosimilars and generic antibiotics, dermatology and transplantation medicines, Sandoz holds leading global positions in areas ranging from generic cardiovascular, central nervous system (CNS), pain and ophthalmology to oncology, respiratory and hormonal therapeutics. Our broad portfolio is backed by a range of state-of-the-art technologies, formulations and devices, including prolonged-release and multiple-unit tablets, creams and gels, orodispersible films, transdermal patches, lyophilized products, implants and inhalers. We have strong scientific roots that have driven many medical innovations, from the first oral penicillin in 1951 to the first biosimilars in Europe and the US; new delivery technologies (e.g. our award-winning Forspiro® inhaler or our fentanyl patch technology) offer genuine improvements over alternative market offerings. We go beyond providing standard products and add value to the healthcare system through a range of support services and value-added medicines including combination formulations. Examples include the “Sandoz Pro” healthcare professionals app pioneered by our Canadian affiliate and the “three-in-one” cardiovascular “polypill” launched by Sandoz Germany in 2015.
Increasing access to medicine is the basis of our day-to-day business model, but we also run a range of targeted corporate responsibility programs to ensure access for those most in need. These programs aim to address specific health needs in underprivileged communities, promote access to medical information and help build capacity.